Fierce Biotech August 27, 2024
Conor Hale

The FDA has cleared its first automated insulin pump for adults with Type 2 diabetes, with Insulet’s Omnipod 5 delivery system opening the door to a population of more than 6 million people.

That includes about 2.5 million people who require multiple injections of insulin per day, according to Insulet. The company also estimates that only a quarter of people taking insulin to manage their Type 2 diabetes are meeting their HbA1c goals of 7% or less.

Now, they will have access to the same technology employed by people with Type 1 diabetes, with Insulet’s tubeless Omnipod system being able to connect with a wearable continuous glucose monitor to automatically detect blood sugar levels and adjust insulin doses accordingly.

“The...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Medical Devices
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article